Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Therapy, End Use, and Region

Description

List of Tables

The hematologic malignancies therapeutics market size is expected to reach USD 148.15 billion by 2034, according to a new study by Polaris Market Research. The report "Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Leukemia, Lymphoma, and Myeloma), Therapy, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Hematologic malignancies therapeutics refer to the medical treatments used to manage blood cancers, which include leukemia, lymphoma, and myeloma. These cancers affect the blood, bone marrow, lymphatic system, or spleen and require specialized therapeutic approaches. The hematologic malignancies therapeutics market share is experiencing significant growth, driven by increasing incidence rates of blood cancers such as leukemia, lymphoma, and myeloma, alongside advancements in treatment options. Key drivers include the rise of immunotherapies, such as CAR-T cell therapies and monoclonal antibodies, as well as the growing adoption of targeted therapies that offer more precise treatment with fewer side effects. Opportunities are emerging in the development of combination therapies, personalized medicine, and the expansion of biosimilars, providing cost-effective alternatives to traditional treatments. Additionally, ongoing research, clinical trials, and regulatory approvals for new therapies continue to drive innovation in the market. Trends such as a shift toward outpatient care increased patient access, and a focus on reducing treatment resistance contribute to the market's overall expansion, positioning it for continued growth in the coming years.

Hematologic Malignancies Therapeutics Market Report Highlights

Leukemia dominates the market in terms of market share due to the high prevalence of conditions such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Significant advancements in targeted therapies are driving its growth. However, lymphoma is the fastest growing segment, driven by the increasing adoption of immunotherapies such as CAR-T cell therapies.

Immunotherapy holds the largest hematologic malignancies therapeutics market share, with CAR-T cell therapies and monoclonal antibodies playing a crucial role in transforming the treatment of hematologic malignancies. Targeted therapies are registering the fastest growth as precision treatments continue to improve outcomes and reduce side effects in blood cancer patients.

Hospital pharmacies hold the largest market share due to their central role in administering complex treatments such as CAR-T cell therapies and chemotherapy. Retail pharmacies are the fastest growing segment, supported by the rising demand for oral oncolytics and at-home treatment options.

North America dominates the market due to high treatment accessibility, advanced healthcare infrastructure, and regulatory support for new therapies. Asia Pacific is the fastest growing region, fueled by increasing cancer incidence, improving healthcare access, and investment in treatment innovations.

Polaris Market Research has segmented the hematologic malignancies therapeutics market report based on disease, therapy, end use, and region:

By Disease Outlook (Revenue-USD Billion, 2020 - 2034)

Leukemia
Lymphoma
Myeloma

By Therapy Outlook (Revenue-USD Billion, 2020 - 2034)

Chemotherapy
Immunotherapy
Targeted Therapy
Others

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

Hospital Pharmacies
Retail Pharmacies
Others

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM1347

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. Global Hematologic Malignancies Therapeutics Market Insights

4.1. Hematologic Malignancies Therapeutics Market - Market Snapshot
4.2. Hematologic Malignancies Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Integration of AI and Machine Learning
  - 4.2.1.2. Shift Toward High-Throughput Experimentation
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Insufficient data volume
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Hematologic Malignancies Therapeutics Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Hematologic Malignancies Therapeutics Market, by Disease

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
5.3. Leukemia
- 5.3.1. Global Hematologic Malignancies Therapeutics Market, by Leukemia, by Region, 2020-2034 (USD Billion)
5.4. Lymphoma
- 5.4.1. Global Hematologic Malignancies Therapeutics Market, by Lymphoma, by Region, 2020-2034 (USD Billion)
5.5. Myeloma
- 5.5.1. Global Hematologic Malignancies Therapeutics Market, by Myeloma, by Region, 2020-2034 (USD Billion)

6. Global Hematologic Malignancies Therapeutics Market, by Therapy

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
6.3. Chemotherapy
- 6.3.1. Global Hematologic Malignancies Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
6.4. Immunotherapy
- 6.4.1. Global Hematologic Malignancies Therapeutics Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
6.5. Targeted Therapy
- 6.5.1. Global Hematologic Malignancies Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
6.6. Others
- 6.6.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Hematologic Malignancies Therapeutics Market, by End Use

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
7.3. Hospital Pharmacies
- 7.3.1. Global Hematologic Malignancies Therapeutics Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
7.4. Others
- 7.4.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Hematologic Malignancies Therapeutics Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Hematologic Malignancies Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. Hematologic Malignancies Therapeutics Market - North America
- 8.3.1. North America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.3.2. North America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.3.3. North America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.3.4. Hematologic Malignancies Therapeutics Market - U.S.
  - 8.3.4.1. U.S.: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.3.5. Hematologic Malignancies Therapeutics Market - Canada
  - 8.3.5.1. Canada: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
8.4. Hematologic Malignancies Therapeutics Market - Europe
- 8.4.1. Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.2. Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.3. Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.4. Hematologic Malignancies Therapeutics Market - UK
  - 8.4.4.1. UK: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.4.2. UK: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.5. Hematologic Malignancies Therapeutics Market - France
  - 8.4.5.1. France: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.5.2. France: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.5.3. France: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.6. Hematologic Malignancies Therapeutics Market - Germany
  - 8.4.6.1. Germany: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.7. Hematologic Malignancies Therapeutics Market - Italy
  - 8.4.7.1. Italy: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.8. Hematologic Malignancies Therapeutics Market - Spain
  - 8.4.8.1. Spain: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.9. Hematologic Malignancies Therapeutics Market - Netherlands
  - 8.4.9.1. Netherlands: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.10. Hematologic Malignancies Therapeutics Market - Russia
  - 8.4.10.1. Russia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.11. Hematologic Malignancies Therapeutics Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
8.5. Hematologic Malignancies Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.4. Hematologic Malignancies Therapeutics Market - China
  - 8.5.4.1. China: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.4.2. China: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.4.3. China: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.5. Hematologic Malignancies Therapeutics Market - India
  - 8.5.5.1. India: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.5.2. India: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.5.3. India: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.6. Hematologic Malignancies Therapeutics Market - Malaysia
  - 8.5.6.1. Malaysia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.7. Hematologic Malignancies Therapeutics Market - Japan
  - 8.5.7.1. Japan: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.8. Hematologic Malignancies Therapeutics Market - Indonesia
  - 8.5.8.1. Indonesia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.9. Hematologic Malignancies Therapeutics Market - South Korea
  - 8.5.9.1. South Korea: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.10. Hematologic Malignancies Therapeutics Market - Australia
  - 8.5.10.1. Australia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.11. Hematologic Malignancies Therapeutics Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
8.6. Hematologic Malignancies Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.4. Hematologic Malignancies Therapeutics Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.5. Hematologic Malignancies Therapeutics Market - UAE
  - 8.6.5.1. UAE: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.6. Hematologic Malignancies Therapeutics Market - Israel
  - 8.6.6.1. Israel: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.7. Hematologic Malignancies Therapeutics Market - South Africa
  - 8.6.7.1. South Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.8. Hematologic Malignancies Therapeutics Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
8.7. Hematologic Malignancies Therapeutics Market - Latin America
- 8.7.1. Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.4. Hematologic Malignancies Therapeutics Market - Mexico
  - 8.7.4.1. Mexico: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.5. Hematologic Malignancies Therapeutics Market - Brazil
  - 8.7.5.1. Brazil: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.6. Hematologic Malignancies Therapeutics Market - Argentina
  - 8.7.6.1. Argentina: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.7. Hematologic Malignancies Therapeutics Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. AbbVie Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Amgen Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Bristol-Myers Squibb Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. F. Hoffmann-La Roche Ltd.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Gilead Sciences Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Johnson & Johnson
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Novartis AG
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Pfizer Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Merck & Co., Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Takeda Pharmaceutical Company Limited
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
10.11. AstraZeneca
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
10.12. BeiGene
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
10.13. Kite Pharma (a subsidiary of Gilead Sciences)
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
10.14. Celgene Corporation (acquired by Bristol-Myers Squibb)
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
10.15. Regeneron Pharmaceuticals, Inc.
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development